

IN THE CLAIMS:

Please amend the claims as follows:

Cancel claims 1-95, without prejudice.

1.-95. (Canceled)

Add new claims 96-179 as follows:

96. (New) An isolated antibody comprising a variable light (VL) domain having an amino acid sequence of SEQ ID NO:11, wherein the antibody immunospecifically binds to a respiratory syncytial virus (RSV) antigen.

97. (New) The antibody of claim 96 further comprising a variable heavy (VH) domain having an amino acid sequence of SEQ ID NO:48.

98. (New) An isolated antibody comprising a VL complementarity determining region (CDR) 1 having an amino acid sequence of SEQ ID NO:39, wherein the antibody immunospecifically binds to a RSV antigen.

99. (New) An isolated antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:5, wherein the antibody immunospecifically binds to a RSV antigen and the antibody is not palivizumab.

100. (New) An isolated antibody comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:6, wherein the antibody immunospecifically binds to a RSV antigen and the antibody is not palivizumab.

101. (New) The antibody of claim 98 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

102. (New) The antibody of claim 98 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

103. (New) The antibody of claim 99 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

104. (New) The antibody of claim 98 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of

SEQ ID NO:6.

105. (New) The antibody of claim 98 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

106. (New) The antibody of claim 98 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

107. (New) The antibody of claim 98 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

108. (New) The antibody of claim 98 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

109. (New) The antibody of claim 98 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

110. (New) The antibody of claim 98 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

111. (New) The antibody of claim 108 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

112. (New) The antibody of claim 99 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

113. (New) The antibody of claim 99 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

114. (New) The antibody of claim 99 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

115. (New) The antibody of claim 99 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

116. (New) The antibody of claim 99 further comprising a VH CDR1 having an

amino acid sequence of SEQ ID NO:10 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

117. (New) The antibody of claim 99 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

118. (New) The antibody of claim 115 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

119. (New) The antibody of claim 101 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

120. (New) The antibody of claim 101 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

121. (New) The antibody of claim 101 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

122. (New) The antibody of claim 101 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

123. (New) The antibody of claim 101 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

124. (New) The antibody of claim 101 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

125. (New) The antibody of claim 122 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

126. (New) The antibody of claim 102 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

127. (New) The antibody of claim 102 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

128. (New) The antibody of claim 102 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

129. (New) The antibody of claim 102 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

130. (New) The antibody of claim 102 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

131. (New) The antibody of claim 102 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

132. (New) The antibody of claim 129 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

133. (New) The antibody of claim 103 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

134. (New) The antibody of claim 103 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

135. (New) The antibody of claim 103 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

136. (New) The antibody of claim 103 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

137. (New) The antibody of claim 103 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

138. (New) The antibody of claim 103 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

139. (New) The antibody of claim 136 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

140. (New) The antibody of claim 104 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

141. (New) The antibody of claim 104 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

142. (New) The antibody of claim 104 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

143. (New) The antibody of claim 104 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

144. (New) The antibody of claim 104 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

145. (New) The antibody of claim 104 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

146. (New) The antibody of claim 143 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

147. (New) A Fab fragment comprising a VH domain having an amino acid sequence of SEQ ID NO:48 and a VL domain having an amino acid sequence of SEQ ID NO:11, wherein the Fab fragment immunospecifically binds to a RSV antigen.

148. (New) A composition comprising one or more species of antibodies, each species of antibody comprising a VH domain having an amino acid sequence of SEQ ID NO:48, wherein each species of antibody immunospecifically binds to a RSV antigen.

149. (New) A composition comprising one or more species of antibodies, each species of antibody comprising a VL domain having an amino acid sequence of SEQ ID NO:11, wherein each species of antibody immunospecifically binds to a RSV antigen.

150. (New) The composition of claim 148 which comprises two or more species of antibodies.

151. (New) The composition of claim 149 which comprises two or more species of antibodies.

152. (New) The composition of claim 149 or 151, wherein each species of antibody further comprises a VH domain having an amino acid sequence of SEQ ID NO:48.

153. (New) A composition comprising one or more species of antibodies, each species of antibody comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10, wherein each species of antibody immunospecifically binds to a RSV antigen.

154. (New) The composition of claim 153 which comprises two or more species of antibodies.

155. (New) A composition comprising one or more species of antibodies, each species of antibody comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19, wherein each species of antibody immunospecifically binds to a RSV antigen.

156. (New) The composition of claim 155 which comprises two or more species of antibodies.

157. (New) A composition comprising one or more species of antibodies, each species of antibody comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20, wherein each species of antibody immunospecifically binds to a RSV antigen.

158. (New) The composition of claim 157 which comprises two or more species of antibodies.

159. (New) A composition comprising one or more species of antibodies, each species of antibody comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:39, wherein each species of antibody immunospecifically binds to a RSV antigen.

160. (New) The composition of claim 159 which comprises two or more species of antibodies.

161. (New) A composition comprising one or more species of antibodies, each species of antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:5,

wherein each species of antibody immunospecifically binds to a RSV antigen and none of the species of antibodies is palivizumab.

162. (New) The composition of claim 161 which comprises two or more species of antibodies.

163. (New) A composition comprising one or more species of antibodies, each species of antibody comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:6, wherein each species of antibody immunospecifically binds to a RSV antigen and none of the species of antibodies is palivizumab.

164. (New) The composition of claim 163 which comprises two or more species of antibodies.

165. (New) A composition comprising A4B4L1FR-S28R and a carrier or excipient.

166. (New) The antibody of claim 96, 97, 98, 99 or 100, wherein the antibody is a monoclonal antibody.

167. (New) The antibody of claim 96, 97, 98, 99 or 100, wherein the antibody is a human antibody.

168. (New) The antibody of claim 96, 97, 98, 99 or 100, wherein the antibody is a humanized antibody.

169. (New) The antibody of claim 96, 97, 98, 99 or 100, wherein the antibody is a multispecific antibody, a chimeric antibody, a Fab fragment, a single-chain Fv or a single chain antibody.

170. (New) The antibody of claim 96, 97, 98, 99 or 100, wherein the antibody is conjugated to a therapeutic or drug moiety.

171. (New) The antibody of claim 96, 97, 98, 99 or 100, wherein the antibody is conjugated to a detectable substance.

172. (New) A pharmaceutical composition comprising the antibody of claim 96, 97, 98, 99 or 100 and a carrier or excipient.

173. (New) A pharmaceutical composition comprising the antibody of claim 170

and a carrier or excipient.

174. (New) A pharmaceutical composition comprising the antibody of claim 171 and a carrier or excipient.

175. (New) The pharmaceutical composition of claim 172 formulated for pulmonary administration.

176. (New) The pharmaceutical composition of claim 172 which is a sustained release formulation.

177. (New) The pharmaceutical composition of claim 172 formulated for parental administration.

178. (New) A lyophilized formulation comprising the antibody of claim 96, 97, 98, 99 or 100.

179. (New) A liquid formulation comprising the antibody of claim 96, 97, 98, 99 or 100.

180. (New) A kit comprising the antibody of claim 96, 97, 98, 99 or 100, in one or more containers, and instructions for use.

181. (New) A kit comprising the antibody of claim 170, in one or more containers, and instructions for use.

182. (New) A kit comprising the antibody of claim 171, in one or more containers, and instructions for use.